Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Chief Patient Officer | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,276 |
Ending reported balance
After 2026-03-18 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-03-17 · Sale · Disposed 1,033 · Balance 12,955 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. Row 2 · 2026-03-17 · Sale · Disposed 748 · Balance 12,207 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. Row 3 · 2026-03-18 · Sale · Disposed 1,762 · Balance 10,445 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. Row 4 · 2026-03-18 · Sale · Disposed 139 · Balance 10,306 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. Row 5 · 2026-03-18 · Sale · Disposed 30 · Balance 10,276 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.
F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dova Pharmaceuticals Inc.
Report date November 12, 2019 · Filed November 12, 2019
Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 1
1 source rowRow 1 · 2019-11-12 · Disposition to issuer · Disposed 9,970 · Balance 0 F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.07 · Expires 2028-12-18 | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-12 · Disposition to issuer · Disposed 250,000 · Balance 0 F2: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $5,357,500.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
F2: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $5,357,500.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.
Provention Bio, Inc.
Report date April 27, 2023 · Filed April 27, 2023
Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.97 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-27 · Disposition to issuer · Disposed 400,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.62 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-04-27 · Disposition to issuer · Disposed 137,750 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.80 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-27 · Disposition to issuer · Disposed 139,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.39 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-04-27 · Disposition to issuer · Disposed 145,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.93 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-04-27 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full.
F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 19, 2026 21:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 30 | $32.85 | $985.50 |
DisclosureSEC source: 0001762572-26-000006 · form4-03192026_090337.xml · nonDerivative · entry 5 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,276 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 21:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 139 | $31.79 | $4,418.64 |
DisclosureSEC source: 0001762572-26-000006 · form4-03192026_090337.xml · nonDerivative · entry 4 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,306 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 21:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,762 | $31.28 | $55,122.06 |
DisclosureSEC source: 0001762572-26-000006 · form4-03192026_090337.xml · nonDerivative · entry 3 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,445 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 21:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 748 | $33.38 | $24,964.80 |
DisclosureSEC source: 0001762572-26-000006 · form4-03192026_090337.xml · nonDerivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,207 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 21:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,033 | $32.74 | $33,819.80 |
DisclosureSEC source: 0001762572-26-000006 · form4-03192026_090337.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,955 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001762572-26-000004 · form4-03172026_090347.xml · derivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2029-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001762572-26-000004 · form4-03172026_090347.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported total includes an aggregate 2,186 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001762572-26-000002 · form4-02192026_090202.xml · derivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001762572-26-000002 · form4-02192026_090202.xml · derivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 200,000 | Not disclosed Strike: $8.93 | Not disclosed |
DisclosureSEC source: 0001493152-23-013904 · ownership.xml · derivative · entry 5 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 145,000 | Not disclosed Strike: $4.39 | Not disclosed |
DisclosureSEC source: 0001493152-23-013904 · ownership.xml · derivative · entry 4 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 139,500 | Not disclosed Strike: $6.80 | Not disclosed |
DisclosureSEC source: 0001493152-23-013904 · ownership.xml · derivative · entry 3 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 139,500 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 137,750 | Not disclosed Strike: $12.62 | Not disclosed |
DisclosureSEC source: 0001493152-23-013904 · ownership.xml · derivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 137,750 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 400,000 | Not disclosed Strike: $14.97 | Not disclosed |
DisclosureSEC source: 0001493152-23-013904 · ownership.xml · derivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 19:16 UTC | Provention Bio, Inc. PRVB · Entity 12101 | SaleCommon Stock | 4,500 | $10.00 | $45,005.40 |
DisclosureSEC source: 0001493152-23-005078 · ownership.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2022. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.02 per share, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:10 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001493152-23-001208 · ownership.xml · derivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock, par value $0.0001 · 200,000 shares Expires 2033-01-10 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 10, 2024) and the remaining 75% will vest and become exercisable monthly over 36 months such that the options are fully vested and exercisable on the four-year anniversary of the grant date (January 10, 2027). Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 20:31 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 20,663 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001493152-22-035096 · ownership.xml · derivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,763 Underlying: Common Stock, par value $0.0001 · 20,663 shares Expires 2030-07-15 F4 · shares: As previously reported on a Form 4 filed on July 16, 2020, on July 15, 2020 the Reporting Person was granted a stock option for 137,750 shares of Common Stock, 55,100 of which option shares vest in four equal annual installments commencing on July 15, 2021 and 82,650 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 20,663 of the 82,650 performance option shares on December 8, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 20,663 option shares. F2 · price: The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F5 · balance_after: Represents the 55,100 time-based option shares referred to in footnote (1) plus the 20,663 vested performance option shares referred to in footnote (4). Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 20:31 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $14.97 | $0.00 |
DisclosureSEC source: 0001493152-22-035096 · ownership.xml · derivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock, par value $0.0001 · 120,000 shares Expires 2030-01-07 F1 · shares: As previously reported on a Form 4 filed on January 8, 2020, on January 7 2020, the Reporting Person was granted a stock option for 400,000 shares of Common Stock, 160,000 of which option shares vest in four equal annual installments commencing on January 7, 2021 and 240,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 120,000 of the 240,000 performance option shares on December 8, 2022 upon the satisfaction of certain performance milestones. This Form 4 is being filed solely to report the vesting of such previously reported 120,000 option shares. F2 · price: The stock options were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F3 · balance_after: Represents the 160,000 time-based option shares referred to in footnote (1) plus the 120,000 vested performance option shares referred to in footnote (1) plus 60,000 vested performance shares which vested on September 2, 2020. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 17:20 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001493152-22-001752 · ownership.xml · derivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock, par value $0.0001 · 145,000 shares Expires 2032-01-18 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 18, 2023) and the remaining 75% will vest and become exercisable monthly over 36 months such that the options are fully vested and exercisable on the four-year anniversary of the grant date (January 18, 2026). Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:39 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 139,500 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001493152-21-011579 · ownership.xml · derivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,500 Underlying: Common Stock, par value $0.0001 · 139,500 shares Expires 2031-05-12 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: 69,750 of the options granted will vest as follows: 25% will vest and become exercisable on May 12, 2022 and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on May 12, 2025. The remaining 69,750 of the options granted will vest and become exercisable, if at all, in three equal installments of 23,250 options, with each such installment triggered upon the achievement of one of three separate corporate performance milestones prior to or during the year 2024. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 18:01 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 137,750 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001493152-20-013476 · ownership.xml · derivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,750 Underlying: Common Stock, par value $0.0001 · 137,750 shares Expires 2030-07-15 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: 55,100 option shares vest in four equal annual installments commencing on July 15, 2021; the remaining 82,650 options shares vest upon completion of certain performance milestones. The completion of each milestone vests 15% of the total option shares. Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 06:15 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 4,500 | $5.43 | $24,435.00 |
DisclosureSEC source: 0001493152-20-004385 · ownership.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.45, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 400,000 | $0.00 Strike: $14.97 | $0.00 |
DisclosureSEC source: 0001493152-20-000369 · ownership.xml · derivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock, par value $0.0001 · 400,000 shares Expires 2030-01-07 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The option was granted on January 7, 2020, pursuant to the Issuer's 2017 Equity Incentive Plan. 160,000 option shares vest in four equal annual installments commencing on January 7, 2021; the remaining 240,000 option shares vest upon completion of certain performance milestones. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 16:35 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 250,000 | Not disclosed Strike: $6.07 | Not disclosed |
DisclosureSEC source: 0001209191-19-056030 · doc4.xml · derivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2028-12-18 F2 · price: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $5,357,500.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. F2 · derivative.exercise_date: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $5,357,500.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 16:35 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | Disposition to issuerCommon Stock | 9,970 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-056030 · doc4.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. F1 · price: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:20 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | SaleCommon Stock | 2,387 | $28.00 | $66,836.00 |
DisclosureSEC source: 0001562180-19-005056 · primarydocument.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,970 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 16:29 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | SaleCommon Stock | 900 | $16.44 | $14,796.00 |
DisclosureSEC source: 0001209191-19-042168 · doc4.xml · nonDerivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,357 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.07 to $16.99 inclusive. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 16:29 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | SaleCommon Stock | 6,680 | $15.10 | $100,868.00 |
DisclosureSEC source: 0001209191-19-042168 · doc4.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,257 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 16:55 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | SaleCommon Stock | 150 | $14.40 | $2,160.00 |
DisclosureSEC source: 0001209191-19-040366 · doc4.xml · nonDerivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,937 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.43 inclusive. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 16:55 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | SaleCommon Stock | 2,237 | $13.77 | $30,803.49 |
DisclosureSEC source: 0001209191-19-040366 · doc4.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,087 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.35 to $14.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 16:48 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | SaleCommon Stock | 2,387 | $8.77 | $20,933.99 |
DisclosureSEC source: 0001209191-19-024262 · doc4.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,324 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.62 to $8.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 17:27 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001209191-18-063713 · doc4.xml · derivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-12-18 F3 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 17:27 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | GrantCommon Stock | 24,711 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-063713 · doc4.xml · nonDerivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,711 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 25% on each of March 29, 2019, June 28, 2019, September 30, 2019 and December 31, 2019. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.